Jefferies Financial Group Reaffirms Buy Rating for GSK (LON:GSK)
by Amy Steele · The Cerbat GemGSK (LON:GSK – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Jefferies Financial Group in a research report issued on Tuesday,London Stock Exchange reports. They currently have a GBX 2,500 price objective on the stock. Jefferies Financial Group’s price target suggests a potential upside of 14.63% from the company’s previous close.
Other research analysts have also recently issued reports about the company. Deutsche Bank Aktiengesellschaft boosted their price target on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Citigroup increased their target price on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th. UBS Group reiterated a “neutral” rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Finally, Berenberg Bank reiterated a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of GBX 2,023.57.
Read Our Latest Research Report on GSK
GSK Stock Performance
Shares of GSK stock traded up GBX 11 during trading hours on Tuesday, reaching GBX 2,181. 55,846,230 shares of the company traded hands, compared to its average volume of 10,100,059. The firm has a 50-day moving average price of GBX 2,105.91 and a 200 day moving average price of GBX 1,885.52. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a 12-month low of GBX 1,263.50 and a 12-month high of GBX 2,282. The company has a market cap of £87.17 billion, a P/E ratio of 15.71, a P/E/G ratio of 1.24 and a beta of 0.35.
GSK (LON:GSK – Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, sell-side analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Anne Beal purchased 196 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were bought at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Also, insider Wendy Becker purchased 411 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were bought at an average price of GBX 1,963 per share, for a total transaction of £8,067.93. Over the last 90 days, insiders have purchased 11,447 shares of company stock worth $24,273,097. 0.20% of the stock is currently owned by corporate insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.